Remaining questions surrounding HER2-low breast cancer – how low can you go?

DESTINY-Breast04: practice-changing results for HER2-low breast cancer

HER2-Low Breast Cancer: DESTINY or Good Science?

The exciting new field of HER2-low breast cancer

Overview of the management of HER2-low breast cancer patients

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Study Says Low Risk Breast Cancer Patients See Similar Survival Rates With Partial Radiation

Clinical outcomes in women with metastatic HER2-low breast cancer in the real world

HER2-low status as a therapeutic target in advanced breast cancer

Remaining questions regarding HER2-low breast cancer

HER2-low expression in breast cancer

HER2-low is not a distinct subtype in inflammatory breast cancer

Treatement of HER2 Low Breast Cancer

Updates on HER2-low breast cancer

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review Conference

ADCs for the treatment of HER2-low breast cancer

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer

Genomic and transcriptomic landscape of HER2-low breast cancer

HER2 Positive, Negative or Low? Breast Cancer Updates in 2023

Survival in premenopausal HR+/HER2- breast cancer with micro-metastasis and 21-gene score